title: Comparable TNF-alpha, IFN-gamma and GM-CSF production by purified normal marrow CD3 cells in response to horse anti-lymphocyte and rabbit antithymocyte globulin.
abstract: In vitro priming of T cell with horse antilymphocyte globulin (HALG) results in cytokine release, and this has been associated with its clinical efficacy in patients with severe aplastic anaemia (SAA). Rabbit antithymocyte globulin (RATG) has been studied less extensively. In this study we compare the in vitro priming effect of HALG and RATG on purified normal marrow T cells: end-points of the study were 1) levels of TNF-alpha (TNF-alpha), IFN-gamma (IFN-gamma) GM-CSF in T cell supernatants, and 2) effect of T cell supernatants on colony formation with or without exogenous GM-CSF TNF-alpha, IFN-gamma and GM-CSF levels were comparable for HALG, RATG and phytohaemagglutinin (PHA). T cell supernatants showed comparable enhancement of colony formation in the presence of recombinant human GM-CSF (rhGM-CSF) and supported colony forming unit granulomacrophage (CFU-GM) growth in the absence of growth factor. This study shows that horse and rabbit derived ALG/ATG and PHA have a comparable in vitro priming effect on T cells: both agents should probably be tested for their clinical efficacy in SAA patients.
authors.affiliation: Sci. Bio. Department of Haematology 2, San Martino Hospital, Genova, Italy. apbacigalupo@smartino.ge.it
authors.forename: G
authors.initials: G
authors.lastname: Piaggio
authors.forename: M
authors.initials: M
authors.lastname: Podestá
authors.forename: A
authors.initials: A
authors.lastname: Pitto
authors.forename: G B
authors.initials: GB
authors.lastname: Pittaluga
authors.forename: A
authors.initials: A
authors.lastname: Isaza
authors.forename: F
authors.initials: F
authors.lastname: Benvenuto
authors.forename: B
authors.initials: B
authors.lastname: Bruno
authors.forename: A
authors.initials: A
authors.lastname: Bacigalupo
mesh_terms: D000741:Anemia, Aplastic / Q000628:therapy*; D000818:Animals; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000276:immunology*; D017252:CD3 Complex / Q000276:immunology*; D002469:Cell Separation; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000096:biosynthesis*; D006410:Hematopoiesis / Q000276:immunology; D006736:Horses; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis*; D010835:Phytohemagglutinins / Q000494:pharmacology; D011817:Rabbits; D012016:Reference Values; D013601:T-Lymphocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
chemical_list: D000961:Antilymphocyte Serum; D017252:CD3 Complex; D010835:Phytohemagglutinins; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor